Strong Compounds Deserve Strong Trial Design: Why Biometrics Strategy Must Start in Phase I
March 24, 2026
By Barbara Day, Principal, Pharmaceutical Practice | Penfield Search Partners Ltd. In drug development, few outcomes are more costly than when a compound fails not because of lack of efficacy